cathepsin
b
ec
cathepsin
h
ec
cathepsin
l
ec
versatil
lysosom
cystein
proteas
respons
intracellular
protein
degrad
involv
number
patholog
condit
includ
tissu
degen
process
present
work
report
synthesi
systemat
evalu
differ
substitut
chalcon
chalconesemicarbazon
diarylpyrazolin
cathepsin
b
h
l
activ
found
preliminari
screen
cystein
proteas
inhibitor
chalconesemicarbazon
better
inhibitor
cystein
proteas
diarylpyrazolin
follow
chalcon
synthes
compound
identifi
best
inhibitor
cathepsin
l
follow
cathepsin
b
cathepsin
h
result
compar
dock
studi
found
compound
result
decreas
energi
interact
activ
site
enzym
semicarbazon
import
bioactiv
compound
possess
differ
biolog
activ
anticonvuls
antimicrobi
antivir
antitumor
antihypertens
antitubercular
compound
also
found
potent
inhibitor
cruzain
cystein
proteas
trypanosoma
cruzi
shown
trypanocid
trypanocid
activ
relat
cruzain
inhibit
tendenc
semicarbazon
falcipain
anoth
protozo
cystein
proteas
also
report
inhibit
varieti
semicarbazon
therefor
semicarbazon
inhibitor
cystein
proteas
potenti
use
prevent
treatment
protozoan
infect
trypanosomiasi
malaria
leishmaniasi
also
report
semicarbazon
aryl
alkyl
carbonyl
compound
inhibit
cystein
proteas
parasit
compar
mammalian
proteas
therefor
indic
possibl
therapeut
use
compound
also
find
use
inhibit
cystein
proteas
associ
carcinogenesi
includ
cathepsin
b
h
l
chalcon
anoth
class
biolog
activ
molecul
known
possess
antimalari
anticanc
antiprotozo
antiinflammatori
antibacteri
antioxid
antifung
activ
also
report
inhibit
variou
enzym
like
tyrosinas
alphaamylas
betalectamas
compound
found
interact
serum
albumin
protein
respons
transport
variou
molecul
includ
drug
present
work
synthes
chalcon
semicarbazon
combin
carbonyland
semicarbazonepharmacophor
result
format
two
isom
report
earlier
evalu
effect
three
import
lysosom
cystein
proteas
cathepsin
b
ec
cystein
proteas
key
factor
pathogenesi
cancer
invas
arthriti
osteoporosi
microbi
infect
cathepsin
b
possess
exo
well
endopeptidas
activ
also
capabl
peptidyldipeptidas
carboxypeptidas
activ
enzym
found
involv
variou
patholog
condit
chronic
inflammatori
diseas
airway
joint
cancer
pancreat
atherosclerosi
rheumatoid
arthriti
alzheim
diseas
etc
cathepsin
h
endo
aminopeptidas
also
involv
mani
diseas
condit
includ
breast
carcinoma
melanoma
tumour
metastasi
head
neck
carcinoma
malign
prostat
cancer
similarli
cathepsin
l
activ
also
report
involv
diseas
osteoarthr
tumorigenesi
ebola
haemorrhag
fever
sever
acut
respiratori
syndrom
leishmaniasi
target
enzym
therefor
one
strategi
develop
new
chemotherapeut
agent
number
diseas
includ
tissu
degen
disord
work
identif
small
molecular
weight
compound
inhibitor
endogen
proteolyt
activ
quest
identif
novel
inhibitor
cathepsin
b
cathepsin
h
recent
report
variou
nonpeptidyl
inhibitor
bischalcon
base
one
thion
ivvi
acyl
hydrazid
triazol
iiii
effect
hydrazon
hydroxyl
chalcon
cycliz
deriv
formyl
benzoyl
pyrazolin
also
establish
enzym
explor
direct
present
work
focus
chalcon
chalconesemicarbazon
cycliz
deriv
inhibitor
cathepsin
b
h
l
intent
synthes
semicarbazon
chalcon
undertaken
keep
view
semicarbazon
possess
azomethin
group
conjunct
extend
pharmacolog
activ
compound
cycliz
pyrazolin
also
report
possess
divers
biolog
activ
antimicrobi
antiamoeb
antiinflammatori
anticanc
antidepress
antitubercular
activ
effect
synthes
compound
observ
cathepsin
b
h
l
establish
structur
activ
relationship
substitut
chalconesemicarbazon
substitut
deriv
structur
activ
relationship
sar
studi
open
chain
cycliz
deriv
result
identif
potenti
inhibitor
among
relat
class
compound
compar
account
differ
moieti
introduc
synthes
compound
cathepsin
b
h
l
three
lysosom
cystein
proteas
inhibit
tendenc
also
evalu
studi
lead
develop
new
inhibitor
enzym
chemic
analyt
grade
fast
garnet
gbc
oaminoazotoluen
diazonium
salt
bana
purchas
bachern
feinchemikalien
ag
switzerland
protein
sampl
concentr
use
amicon
stir
cell
ym
membran
nitrogen
pressur
psi
sourc
enzym
fresh
goat
liver
obtain
local
slaughter
hous
melt
point
taken
open
capillari
uncorrect
progress
reaction
monitor
silica
gel
g
plate
use
iodin
vapor
visual
agent
elisa
plate
reader
use
measur
absorb
visibl
rang
spectrofug
use
centrifug
purpos
ir
spectra
record
horizon
mhz
spectromet
nmr
spectra
record
bruker
mhz
instrument
chemic
shift
express
ppm
unit
intern
tm
standard
commerci
avail
reagent
use
asreceiv
titl
compound
synthes
accord
scheme
acetophenon
mol
ad
equimolar
quantiti
substitut
benzaldehyd
mol
dissolv
methanol
ml
solut
equimolar
naoh
pellet
mol
ad
reaction
mixtur
stir
min
room
temperatur
excess
methanol
ad
stir
next
min
room
temperatur
dilut
cold
water
product
separ
filter
wash
water
neutral
result
chalcon
purifi
recrystal
methanol
structur
character
use
melt
point
compar
literatur
melt
point
ir
nmr
aqueou
semicarbazid
hydrochlorid
mol
sodium
acet
mol
dissolv
solut
ad
ethanol
solut
substitut
mol
drop
concentr
hydrochlor
acid
ad
reaction
mixtur
stir
c
monitor
tlc
complet
reaction
mixtur
pour
ice
precipit
obtain
filter
wash
water
dri
recrystal
ethanol
product
thu
obtain
found
possess
two
stereoisomer
form
fig
separ
column
two
isom
character
use
h
nmr
aqueou
sodium
hydroxid
mol
semicarbazid
hydrochlorid
mol
dissolv
solut
ad
solut
substitut
mol
ethanol
ml
reflux
h
tlc
monitor
extens
done
solvent
evapor
solid
obtain
filter
wash
water
neutral
reaction
dri
recrystal
ethanol
structur
character
use
melt
point
compar
literatur
melt
point
ir
nmr
spectroscop
techniqu
purif
step
carri
c
cathepsin
b
h
l
extract
purifi
goat
liver
establish
procedur
report
previous
includ
step
aceton
powder
prepar
homogen
acid
autolysi
nh
fraction
molecular
siev
chromatographi
sephadex
ion
exchang
chromatographi
cm
sephadex
deae
sephadex
specif
activ
cathepsin
b
h
l
equal
nmolminmg
nmolminmg
nmolminmg
respect
experi
conduct
triplic
describ
previous
endogen
proteolyt
studi
cathepsin
b
l
activ
determin
use
bana
substrat
ph
respect
wherea
cathepsin
h
activ
determin
use
assay
use
respect
substrat
experi
perform
triplic
concentr
activ
calcul
respect
control
compound
ad
equival
amount
solvent
present
enzym
assay
similarli
conduct
lower
concentr
compound
observ
inhibitori
effect
compound
vari
concentr
result
present
fig
cathepsin
b
h
l
respect
establish
inhibitori
action
substitut
chalconesemicarbazon
substitut
deriv
cathepsin
b
h
l
experi
design
evalu
type
inhibit
determin
tabl
dock
studi
perform
use
igemdock
softwar
conduct
small
molecular
weight
ligand
prepar
use
marvin
sketch
save
mdl
mol
file
enzym
structur
activ
site
retriev
protein
data
bank
http
wwwrcsborg
b
pyspdb
h
nagpdb
csw
prepar
ligand
bind
site
load
igemdock
programm
dock
run
set
ga
paramet
standard
dock
accuraci
set
dock
experi
show
decreas
energi
enzym
ligand
interact
e
total
result
hbond
van
der
waal
interact
present
tabl
supplementari
data
synthesi
chalcon
substitut
benzaldehyd
acetophenon
carri
use
claisenschmidt
condens
substitut
chalconesemicarbazon
substitut
synthes
chalcon
use
semicarbazid
hydrochlorid
scheme
establish
structur
chalcon
correspond
semicarbazon
synthes
structur
elucid
use
melt
point
ir
nmr
spectra
synthesi
chalconesemicarbazon
result
two
isomer
form
two
isomer
form
separ
column
chromatographi
silica
gel
use
petroleum
ether
ethyl
acet
eluent
separ
isom
character
h
nmr
data
isom
obtain
character
basi
interact
lone
pair
nitrogen
c
h
proton
explain
curphymorrison
chemic
shift
lone
pair
nitrogen
syn
c
h
bond
proton
shift
upfield
show
lower
valu
lone
pair
nitrogen
anti
c
h
bond
proton
shift
downfield
conclus
arriv
basi
molecular
model
studi
lone
pair
nitrogen
syn
c
h
scheme
minim
energi
molecular
model
fig
clearli
indic
lone
pair
nitrogen
optim
posit
affect
shield
c
h
also
c
h
extent
extens
conjug
lone
pair
nitrogen
anti
c
h
molecular
model
minim
energi
structur
shown
figur
clear
ca
nt
effect
ch
ch
proton
compar
h
nmr
peak
c
h
c
h
chalcon
chalconesemicarbazon
distinct
shield
effect
observ
due
substitut
adjac
c
group
c
n
nhconh
isomer
form
report
first
time
although
larg
number
report
avail
literatur
synthesi
compound
case
poch
pno
substitut
isom
one
isom
form
ie
respect
cycliz
chalconesemicarbazon
diarylpyrazolin
obtain
two
isomer
form
result
singl
product
contrast
two
isomer
form
pyrazolin
report
shekarchi
et
al
h
nmr
spectra
characterist
abx
pattern
obtain
proteolyt
activ
inhibit
appreci
presenc
compound
case
inhibit
achiev
concentr
moreov
inhibit
h
less
h
emphas
compound
inhibit
proteolyt
activ
revers
case
chalcon
chloro
unsubstitut
compound
show
inhibit
chalconesemicarbazon
diaryl
pyrazolin
chloro
nitro
substitut
compound
show
inhibit
addit
oand
pmethoxi
substitut
chalconesemicarbazon
omethoxi
pyrazolin
also
exhibit
inhibit
unsubstitut
methyl
substitut
chalconesemicarbazon
pyrazolin
exert
inhibit
lesser
extent
establish
inhibit
endogen
proteolyt
activ
presenc
chalcon
deriv
ph
proteolyt
activ
attribut
cystein
proteas
thought
proper
studi
effect
synthes
compound
purifi
cathepsin
b
h
l
effect
differ
substitut
chalcon
chalconesemicarbazon
diarylpyrazolin
activ
cathepsin
b
h
l
vari
concentr
shown
fig
plot
residu
activ
versu
concentr
differ
compound
observ
particular
concentr
synthes
compound
inhibit
cathepsin
l
activ
cathepsin
b
h
type
inhibit
caus
variou
compound
determin
lineweaverburk
doubl
reciproc
plot
order
establish
inhibit
abil
consider
compound
result
compar
potent
inhibitor
cathepsin
b
eg
leupeptin
cathepsin
h
eg
leuch
cl
respect
report
literatur
leupeptin
potent
peptid
inhibitor
cathepsin
b
inhibit
goat
brain
cathepsin
b
competit
k
valu
wherea
k
valu
human
liver
cathepsin
b
report
contrast
k
valu
human
liver
cathepsin
h
report
k
valu
goat
brain
cathepsin
l
report
evalu
type
inhibit
caus
differ
chalcon
chalconesemicarbazon
diarylpyrazolin
cathepsin
b
h
l
activ
measur
vari
substrat
ie
bana
leu
concentr
presenc
absenc
fix
concentr
compound
plot
straight
line
intersect
yaxi
show
valu
v
max
remain
constant
compound
wherea
valu
k
chang
compound
studi
suggest
chalcon
chalconesemicarbazon
diarylpyrazolin
competit
inhibitor
cathepsin
b
h
l
use
lineweaverburk
equat
competit
inhibit
k
valu
calcul
present
tabl
lineweaverburk
plot
differ
chalcon
chalconesemicarbazon
diarylpyrazolin
cathepsin
b
h
l
shown
fig
proteas
contribut
tumour
cell
invas
angiogenesi
commonli
associ
metastasi
recogn
cystein
proteas
play
pivot
role
cancer
progress
cathepsin
studi
shown
cathepsin
b
h
l
signific
import
involv
variou
patholog
oncogen
process
though
enzym
intens
studi
valuabl
target
drug
discoveri
develop
number
peptid
nonpeptid
inhibitor
describ
literatur
toward
endevour
synthes
chalcon
semicarbazon
pyrazolin
deriv
differ
function
order
explor
inhibitori
potenti
import
enzym
keep
view
inhibitori
potenti
semicarbazon
pyrazolin
well
chalcon
cystein
proteas
work
envisag
combin
two
activ
pharmacophor
observ
chalconesemicarbazon
show
maximum
inhibit
cycliz
precursor
pyrazolin
follow
chalcon
activ
cathepsin
b
cathepsin
h
wherea
cathespin
l
chalcon
chalconesemicarbazon
found
show
inhibit
pyrazolin
result
discuss
later
next
section
along
result
obtain
molecular
dock
among
substitut
chalcon
chalconesemicarbazon
pyrazolin
compound
bear
electron
withdraw
moieti
found
inhibitori
probabl
induc
nucleophil
charact
site
attack
shown
scheme
result
obtain
compar
potenti
inhibitor
cathepsin
b
l
eg
leupeptin
cathepsin
h
eg
leuch
cl
respect
observ
leupeptin
show
inhibit
concentr
cathepsin
b
wherea
show
inhibit
concentr
cathepsin
h
inhibit
concentr
cathepsin
l
accord
previous
report
result
similarli
leuch
cl
show
inhibit
concentr
cathepsin
b
wherea
show
inhibit
concentr
cathepsin
h
inhibit
concentr
cathepsin
l
result
obtain
compar
earlier
result
report
brain
cathepsin
h
cathepsin
b
cathepsin
l
dock
approach
use
studi
interact
compound
activ
site
cathepsin
b
h
l
observ
bind
pose
individu
compound
individu
bind
pose
compound
assess
interact
activ
site
enzym
analyz
empir
score
function
igemdock
estim
sum
total
van
der
waal
hbond
electrostat
energi
tabl
supplementari
data
present
data
dock
studi
differ
chalcon
acycl
cyclic
semicarbazon
deriv
cathepsin
b
activ
site
b
pyspdb
result
clearli
indic
bind
energi
chalcon
less
pyrazolin
deriv
less
open
chain
semicarbazon
bind
energi
chalcon
dock
result
explain
titl
compound
may
potent
inhibitor
proteas
activ
extent
specif
pepidyl
inhibitor
certainli
suggest
differenti
inhibitori
pattern
compound
cathepsin
b
activ
howev
maximum
interact
observ
bana
score
decreas
total
energi
leupeptincathepsin
b
come
contribut
van
der
waal
interact
score
compar
hbond
score
leupeptincathepsin
b
bind
energi
due
peptideprotein
interact
leupeptin
peptidyl
natur
therefor
flexibl
molecul
bind
effect
enzym
activ
site
result
higher
bind
energi
igemdock
provid
algorithm
flexibl
dock
approach
ligand
protein
therefor
flexibl
ligand
like
leupeptin
show
larger
decreas
total
energi
compar
molecul
studi
smaller
structur
possess
lesser
flexibl
compar
leupeptin
therefor
bind
energi
titl
compound
less
leupeptin
quest
synthes
potent
inhibitor
enzym
structureact
relationship
requir
cyclic
acycl
analogu
studi
variou
pharmacodynam
reaction
molecul
act
drug
encount
vivo
cycliz
oxid
reduct
etc
provid
compar
account
vitro
studi
insilico
studi
structur
relat
compound
isom
compound
synthes
start
materi
open
chain
analogu
intermedi
therefor
need
screen
inhibitori
potenti
along
product
ie
cycliz
deriv
pyrazolin
order
establish
structur
activ
relationship
direct
present
studi
undertaken
evalu
effect
substitut
chalconesemicarbazon
open
chain
compound
cyclic
analogu
ie
substitut
deriv
activ
cathepsin
b
proteas
immens
import
synthet
studi
semicarbazon
came
across
presenc
two
stereoisom
prepar
dock
experi
conduct
two
isom
also
differenti
effect
observ
tabl
supplementari
data
result
dock
studi
support
vitro
experiment
studi
conduct
liver
cathepsin
b
observ
chalcon
less
inhibitori
enzym
activ
wherea
semicarbazon
pyrazolin
deriv
quit
surpris
chalcon
unsatur
carbonyl
group
seem
respons
toward
thiol
attack
cystein
present
activ
site
enzym
result
insilico
dock
experi
well
vitro
solut
studi
clearli
indic
presenc
azomethin
carboxamid
might
provid
larger
interact
bind
compound
enzym
activ
site
exert
inhibit
precursor
chalcon
confirm
enzymeligand
interact
studi
fig
show
bind
inhibitori
compound
activ
site
cathepsin
b
ligand
shown
pink
residu
involv
hbond
vander
waal
interact
shown
green
grey
respect
clearli
observ
residu
present
catalyt
site
enzym
involv
bind
compound
base
interact
mechan
inhibit
scheme
chalcon
chalconesemicarbazon
propos
basi
previous
report
inhibit
cathepsin
l
anoth
import
cystein
proteas
thiosemicarbazon
thiolat
attack
nucleophil
site
chalcon
chalconesemicarbazon
later
stabil
bind
site
addit
amino
acid
residu
also
involv
stabil
compound
bind
site
pyrazolin
also
better
inhibitor
cathepsin
b
activ
chalcon
emphas
import
bind
compound
activ
site
though
pyrazolin
lack
nucleophil
site
structur
still
show
better
inhibitori
potenti
probabl
due
presenc
side
chain
carboxamid
nitrogen
ring
altogeth
provid
larger
bind
area
enzym
site
among
cycliz
pyrazolin
less
inhibitori
open
chain
semicarbazon
interpret
acycl
compound
interact
activ
site
straight
natur
extent
peptidyl
inhibitor
certainli
greater
cycliz
pyrazolin
deriv
give
understand
inhibit
caus
target
compound
structur
basi
similar
trend
observ
cathepsin
h
howev
cathepsin
h
inhibitori
compound
seri
found
fig
show
bind
inhibitori
compound
activ
site
cathepsin
h
bind
energi
titl
compound
amino
acyl
bind
site
cathepsin
h
nag
present
tabl
supplementari
data
experiment
result
obtain
correl
ligandbind
interact
observ
bind
energi
comput
come
seri
inhibitori
compound
show
decreas
bind
energi
toward
higher
side
bind
energi
show
effect
interact
enzym
bind
site
inhibitori
compound
may
respons
inhibit
pattern
fig
show
bind
inhibitori
compound
activ
site
cathepsin
l
result
dock
studi
support
vitro
experiment
studi
conduct
goat
liver
cathepsin
l
bind
energi
titl
compound
amino
acyl
bind
site
cathepsin
l
csw
present
tabl
supplementari
data
bind
energi
found
respect
one
import
aspect
present
work
compris
synthesi
isol
two
stereoisom
chalconesemicarbazon
report
earlier
synthesi
type
molecul
larg
report
literatur
keep
view
vast
biolog
activ
precursor
pyrazolin
pyrazol
synthes
titl
compound
evalu
better
inhibitor
cathepsin
l
cathepsin
b
follow
cathepsin
h
best
inhibitor
cathepsin
b
evalu
e
semicarbazid
k
valu
cathepsin
h
e
semicarbazid
show
maximum
inhibit
k
valu
cathepsin
l
e
semicarbazid
show
maximum
inhibit
k
valu
chalconesemicarbazon
inhibit
three
enzym
effect
follow
pyrazolin
chalcon
